Alzheimer's may be delayed through lifestyle changes, new studies show
Richardson, now 51, remembers crying when she got the news. 'I was terrified,' she said. 'It's a horrible, horrible disease with no cure.'
So Richardson, a business owner in Richmond, Virginia, decided to make whatever changes she could to reduce her risk of the disease. 'I do what I can to get enough sleep. I keep active. I try to eat well and maintain a healthy weight, and I'm always working my brain to learn new things,' she said.
Two new studies being presented at the Alzheimer's Association International Conference meeting Monday in Toronto may give some hope to Richardson and others who carry a genetic risk for the disease. Both new studies build on previous evidence that diet, certain brain training exercises and physical activity can delay the loss of memory and slow the decline of other cognitive abilities.
One study looked at the impact of walking on 2,985 Black and white older adults who were tested for APOE status and were followed for 10 years. Each year, the participants were questioned about the amount of walking they did, and at multiple points during the follow-up period, their cognitive status was evaluated with standardized exams.
Overall, participants with the APOE4 gene mutation showed steeper declines in cognition compared with those with other forms of the gene that don't raise the risk of Alzheimer's. While walking appeared to have a protective effect on all the participants, it was strongest among those with APOE4.
The risk of developing Alzheimer's among those with two copies of APOE4 is 12 times that of women with none and four times that of men with none, said the study's senior author, Cindy Barha, an assistant professor of neuroscience at the University of Calgary and Canada Research chair in neuroscience, brain health and exercise.
That changed significantly if people walked. Overall, women benefited more.
A 10% higher amount of self-reported walking was associated with a 4.7% increase in complex thinking performance over time in women and a 2.6% increase in men.
Among APOE4 carriers, men appeared to benefit more. A 10% higher amount of self-reported walking was associated with an 8.5% increase in global cognitive performance over time in women and a 12% increase in men. That was a surprise to the researchers, who expected that women would continue to benefit more.
Walking seems to keep brains healthier by pumping up levels of brain-derived neurotrophic factor (BDNF), a protein that's known to support the health of brain cells, Barha said. Other proteins in the brain may be involved, as well.
'BDNF is like fertilizer for your brain that is naturally produced, especially when you are being physically active, such as when you are walking,' Barha said. 'It helps brain cells survive, grow and form stronger connections; this supports memory, learning and mood, especially in the hippocampus, which is the brain's memory center.'
A limitation of the study is that it didn't track how fast or how frequently the participants walked.
Dementia risk modified through lifestyle
The second international study, led by researchers in Finland, found that a combination of lifestyle modifications could also benefit people with the APOE4 variation more than those with other mutations.
The study included 2,469 participants from France, Japan and Finland who were randomly assigned to receive multi-focus lifestyle interventions or not. Among the participants were 709 APOE4 carriers.
Included in the lifestyle modifications were:
Cognitive training, either computer-based or with paper and pencil.
Physical activity, including group-based physical group exercise sessions lasting 90 minutes and an exercise program supervised by physiotherapists at the gym.
Dietary counseling.
A preliminary analysis revealed that the benefit of the intervention was greater among the APOE4 carriers.
Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway is that the risk for dementia, even in people with genetic predisposition, can be modified through lifestyle.
There was about a fourfold greater benefit in those who were positive for APOE4, said Lehtisalo, who is also a visiting researcher at the University of Eastern Finland.
The hope is that future research will reveal whether there is a specific window of time during which the modifications are more effective, she said.
Dr. Cynthia Boyd, a professor of medicine and director of the division of geriatric medicine and gerontology at Johns Hopkins Medicine, said the studies show 'there is something concrete we can all do to decrease the risk of cognitive decline.'
'Walking and other lifestyle modifications can be protective for the brain,' said Boyd, who wasn't involved in the new research.
Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, said that to optimize brain and cognitive health, it's a good idea for everyone, regardless of genetic risk, to engage in physical activity, maintain a good diet and monitor other risk factors linked to dementia.
'Sometimes initiating new healthy behaviors is difficult for people," Brickman said. "Knowledge of being at increased risk for Alzheimer's disease by virtue of having an APOE4 allele may help inspire or motivate lifestyle changes to mitigate that risk.'
This article was originally published on NBCNews.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
13 minutes ago
- Forbes
How AI Is Transforming Healthcare In 2025
Ashish Sukhadeve, Founder and CEO of Analytics Insight, providing organizations with strategic insights on disruptive technologies. In terms of its transformative effect, AI is doing for healthcare what electricity did for the industry. According to Fortune Business Insights, the global AI healthcare market was valued at $29.01 billion in 2024, and it's projected to grow to $504.17 billion by 2032. This represents a massive CAGR of 44%. For healthcare leaders, the time to act is now; AI is rapidly advancing areas such as illness prevention, diagnostics and drug discovery, and it has the potential to significantly reduce administrative burdens. Here are just some of the areas to follow when it comes to AI in the sector: Preventing Illness I think one of AI's most valuable contributions is its ability to prevent illness. There are many wearables, AI health apps and the Internet of Medical Things (IoMT) available now. These consumer applications enable individuals to take charge of their own health. They allow users to monitor everything from heart rates to sleep cycles, turning passive patients into proactive participants. Doctors also benefit. AI helps them understand a patient's daily habits, risks and medical history. This improves their ability to offer personalized care. I see prevention, powered by data, as becoming the new normal. Diagnosis AI also excels in medical imaging and diagnostics. At Massachusetts General Hospital and MIT, AI detected lung nodules with 94% accuracy, outperforming radiologists, who achieved 65%. Similar results have been found for breast cancer detection. According to the Harvard School of Public Health, AI in diagnostics may reduce treatment costs by 50% and improve outcomes by 40%. AI is not just reducing medical errors; it is reducing medical anxiety. I believe with AI improving both accuracy and outcomes, healthcare leaders must treat diagnostics not as a back-office upgrade, but as a frontline opportunity for transformation. Drug Discovery Bringing a drug to market can take over 10 years and cost $172 million on average. Only 13.8% of compounds make it to approval. AI can help reduce this timeline dramatically. Systems like IBM Watson can process vast amounts of medical journals and case studies. DeepMind uses neural networks to solve complex health problems with learning algorithms. AstraZeneca's AI, trained on data from 500,000 people, can now predict diseases like Alzheimer's before symptoms appear. These tools can be used not only to improve timelines but also to save countless lives. Caring For The Aging Population As populations age, the demand for elder care rises. AI-powered robots are easing this burden, even when it comes to things like laundry. They are increasingly used to assist in physical therapy, provide companionship and reduce hospital visits. These machines can now hold conversations that stimulate mental engagement in older adults. The lesson is clear: Embracing AI not only addresses labor shortages but also opens new paths to compassionate, scalable elder care. Administration Support AI is improving what patients don't see, the administration. Microsoft's Dragon Copilot can create real-time notes during clinical consultations. Germany's Elea AI reports that it can cut testing and diagnosis from "weeks to hours." These and many other tools are giving doctors more time focusing on patient care. These tools are also helping save time when it comes to clinical decision making, and as evidenced by the Alzheimer's prediction example, AI increasingly supports early warnings. It can now identify high-risk patients using data patterns, including genetic and lifestyle factors. Tools like ChatRWD are replacing and outperforming generic AI models. Conclusion AI is not replacing doctors but empowering them. It now impacts every layer of healthcare, from diagnosis to prevention, from robots to research. Patients can be better informed. Doctors are better equipped. Systems are more efficient. In 2025, I believe the most important medical tool is not a scalpel; it's data, and AI is the surgeon. The future of healthcare is not waiting on some distant horizon; it's already here.
Yahoo
30 minutes ago
- Yahoo
New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains
Alzheimer's Drug Discovery Foundation calls for guidelines for FDA-approved blood tests to continue momentum toward precision medicine NEW YORK, July 30, 2025 /PRNewswire/ -- Expanding the use of Alzheimer's blood tests is crucial to usher in a new era of precision medicine and bring Alzheimer's disease into mainstream care. The new clinical practice guidelines for blood biomarkers announced today by the Alzheimer's Association represent a first step in this effort, but further direction is needed to address newly FDA-approved tests as the diagnostic landscape continues to evolve. "Replacing more invasive PET scans and CSF tests, when appropriate, with blood tests will be a major step toward the future we envision, where we can detect and diagnose Alzheimer's sooner, allowing for earlier intervention and even prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "These guidelines signal progress, but with the science moving quickly, it's essential that clinical recommendations keep pace – especially with Fujirebio's blood test approved by the FDA and more to follow." The new guidelines are limited to specialty care, apply only to patients with cognitive impairment, and exclude several blood tests, including Fujirebio's. Still, they reflect critical momentum, recommending blood biomarkers with ≥90% sensitivity and specificity to replace more invasive and costly confirmatory tests like PET imaging or cerebrospinal fluid (CSF) testing during Alzheimer's diagnosis. As of now, only C2N's PrecivityAD2 test meets these requirements. Tests with ≥90% sensitivity and ≥75% specificity are recommended to be used for triage, with negative results ruling out Alzheimer's, while positive results should be confirmed with PET or CSF. While amyloid blood tests are a critical first step, the ADDF is focused on advancing next-generation biomarkers through its Diagnostics Accelerator (DxA) – a $100 million global initiative supported by the late Leonard A. Lauder, Bill Gates, Jeff Bezos, and other leading philanthropists – that reflect the broader biology of aging and align with today's robust drug pipeline where over 70% of drugs target non-amyloid pathways. "The future of Alzheimer's care lies in precision medicine. To get there, we need a full spectrum of validated biomarkers — and robust clinical guidelines to help providers use them effectively," added Dr. Fillit. "In the future, digital biomarkers and blood tests will be used side-by-side to detect the disease early, track its progression, and guide treatment based on each patient's unique biology." About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: About the Diagnostics Accelerator (DxA)The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. View original content to download multimedia: SOURCE Alzheimer's Drug Discovery Foundation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNN
3 hours ago
- CNN
Food assistance benefits are tied to slower cognitive decline in older adults, new study suggests
For older adults who may otherwise be food-insecure, participating in food assistance benefits may be associated with a slower cognitive decline as they age, according to new research. Compared with eligible people who were not participating in the US Supplemental Nutritional Assistance Program, SNAP participants showed a slower decline in cognitive function during a 10-year period, essentially maintaining up to three additional years of cognitive health, according to the study presented Wednesday at the Alzheimer's Association International Conference in Toronto. 'We expected that SNAP might be protective for cognitive health based on prior research linking food insecurity to faster cognitive decline. But what did surprise us was the persistence of the effect over a decade — and the fact that the benefit was equivalent to preserving two to three extra years of cognitive health,' Linlin Da, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, said in an email. 'This study is important because it shows that supporting basic needs like food access can have long-term benefits for brain health, something not widely recognized,' Da said. 'In a time when we're seeking ways to delay or prevent Alzheimer's disease and related dementia, this suggests that public health and social policy can play a role alongside medical approaches.' It's estimated that nearly 37% of SNAP participants are in households with older adults or people with disabilities, and on average, SNAP participants may receive an estimated $6.16 per day per person in benefits. SNAP, known previously as the Food Stamp Program, helped an average of more than 41 million low-income people in the United States in a typical month last year, according to the Center on Budget and Policy Priorities. Now, President Trump's One Big Beautiful Bill Act makes the largest cuts to food stamps in the program's 86-year history, jeopardizing assistance for millions of people. The nonpartisan Congressional Budget Office estimates that the law will reduce federal spending on SNAP by almost $187 billion over the next decade. Some public health experts worry that while cuts to SNAP would lead to budgetary savings, it also could produce higher rates of food insecurity and poorer health outcomes in the long run, according to the nonprofit KFF, formerly known as the Kaiser Family Foundation. And some Democratic state leaders are warning about potential consequences. 'During a time when many American families are already struggling, food assistance programs such as SNAP are more essential than ever,' Illinois Gov. JB Pritzker said in a news release Tuesday. 'Under the veneer of 'cost savings,' the Trump Administration is slashing benefits and threatening the well-being of hundreds of thousands of Illinoisans, putting their health and welfare at risk. Our state deserves better.' The researchers on the new study, from the University of Georgia, analyzed data on more than 2,000 adults 50 and older across the United States. About half of them were enrolled in SNAP in 2010, and the other half were eligible for SNAP but did not participate in the program. Every two years between 2010 and 2020, the researchers interviewed the study participants to assess their cognition, memory and executive function, including their ability to carry out tasks or to plan. Each person was given a cognitive score based on the assessments. The assessments, which have not yet been published in a peer-reviewed journal, showed that those enrolled in SNAP had a slower rate of cognitive decline in cognition, memory and executive function during the 10-year period. 'The decline in global cognitive function was 0.10 points slower per year for SNAP participants compared to nonparticipants,' Da said. 'While that may sound small, over a 10-year period, this adds up to about one full point of preserved cognition. To put it in clinical terms, this slower decline could delay the onset of mild cognitive impairment by nearly a decade for someone starting at a healthy cognitive baseline.' When the researchers analyzed their data by race and ethnicity, they found that there was a slightly faster decline in cognition and memory among Black and Hispanic adults compared with White adults, but no significant racial differences were observed for executive function. However, SNAP participation was linked with much stronger cognitive benefits and slower decline among the White adults. As a 10-year study, the new research covers 'a good length of time' to determine the benefits of diet and SNAP as associated with cognitive health, Dr. Shae Datta, a neurologist at NYU Langone Health and brand partner for the supplement company Qunol, said in an email. 'Having the means to buy nutritious food is important for preventing cognitive decline,' said Datta, who was not involved in the new study. 'This study suggested that SNAP participation, or any nutritional support program can delay the onset of cognitive impairment or dementia. Translating in a greater ability to manage their activities of daily living and remain independent longer.' While the new study suggests only an association between SNAP participation and cognitive decline, rather than a causal relationship, the researchers emphasized that not having adequate access to food can negatively affect cognitive function. SNAP participation may help improve someone's nutritional intake, thus potentially slowing cognitive decline. 'When people don't have access to healthy nutrition programs, they may have inadequate intake of, for example, brain healthy fats, omega-3 fatty acids, which are found in fish, fish like lake trout, mackerel, herring, albacore tuna, sardines and wild salmon,' said preventive neurologist Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida, who was not involved in the new study. 'Having a balanced diet can neutralize a lot of the risk elements related to developing cognitive decline. The way that I would think about this is, the Mediterranean-style diet is by far the most evidence-based when it comes to reducing the risk of cognitive decline,' Isaacson said. 'But a Mediterranean-style diet is rich in green, leafy vegetables. Vegetables are expensive. Fatty fish are expensive. So nutrition assistance programs can really fill the gap.' A Mediterranean-style diet includes mostly vegetables, fruits, beans, nuts, lentils, whole grains and healthy fats, such as extra virgin olive oil and avocados. The diet may include a moderate amount of natural cheese and yogurt, but it is low in red meat and sugar. Overall, the potential health benefits of participating in a food assistance program for an older adult who otherwise would be food-insecure are based on whether that adult uses the program to access brain healthy foods while taking other steps to maintain cognitive health, said Isaacson, who established one of the first Alzheimer's prevention clinics in the United States. 'You can't eat a magic blueberry and think you're going to prevent Alzheimer's disease,' he said. 'Healthy nutrition, exercising on a regular basis, seeing a doctor regularly to control blood pressure, cholesterol, diabetes, vascular risk factors – you need to do all of these different things to have the most benefit.' CNN's Nathaniel Meyersohn contributed to this report.